FACS staining confirmed that Pax5 was markedly decreased in BM CD93+ BMBP, particularly in CSF1R+ but not CSF1R− subsets, from mice with 4T1.2 or Mogp cancers (Fig. 6a and Supplementary Fig. 9a–c). Here, PAX5 is linked to cancer.